BiotechTube
Hal Allergy

Hal Allergy

Leiden, Netherlands· Est.
hal-allergy.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

HAL Allergy is a well-established, private European leader in allergen immunotherapy (AIT), with a 65-year history. The company operates a fully integrated model from R&D to commercial distribution, with a current portfolio of approved AIT products for respiratory allergies and a promising clinical pipeline targeting both respiratory and food allergies. Positioned in the Leiden Bio Science Park, HAL Allergy leverages proprietary technology to develop modified allergen extracts, aiming to address the growing global burden of allergic diseases through its therapeutic innovations.

Allergic DiseasesRespiratory AllergiesFood Allergies

Technology Platform

Proprietary technology for producing modified allergen extracts for subcutaneous and sublingual immunotherapy (AIT).

Funding History

1
UndisclosedUndisclosed

Opportunities

The rising global prevalence of allergic diseases, particularly life-threatening food allergies, creates a significant and growing market for disease-modifying therapies.
HAL Allergy's expansion into clinical programs for peanut and tree nut allergies addresses a major unmet medical need with limited competition, representing a substantial blue-ocean growth opportunity beyond its core respiratory business.

Risk Factors

Key risks include clinical trial failure or safety setbacks in its high-stakes food allergy pipeline, intense competition in the AIT market from both established players and novel modalities, and pricing/reimbursement pressures across European healthcare systems.
Operational risks are tied to the complex biological manufacturing process for allergen extracts.

Competitive Landscape

HAL Allergy competes in the European AIT market with other specialized firms like ALK-Abelló and Stallergenes Greer. In the emerging food allergy segment, it faces competition from companies such as DBV Technologies and the legacy programs of Aimmune Therapeutics (now Nestlé Health Science). The competitive landscape requires continuous innovation in efficacy, safety, and patient convenience.

More companies in Biologics / Biosimilars →More companies in Netherlands →